Pelthos Therapeutics, Inc. (PTHS)
22.85
+0.20
(+0.88%)
USD |
NYAM |
Sep 21, 16:00
22.85
0.00 (0.00%)
After-Hours: 20:00
Pelthos Therapeutics Enterprise Value : 132.78M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 132.78M |
| September 17, 2026 | 131.77M |
| September 16, 2026 | 120.76M |
| September 15, 2026 | 124.11M |
| September 14, 2026 | 130.14M |
| September 11, 2026 | 129.99M |
| September 10, 2026 | 131.96M |
| September 09, 2026 | 135.64M |
| September 08, 2026 | 139.84M |
| September 04, 2026 | 139.10M |
| September 03, 2026 | 139.13M |
| September 02, 2026 | 141.63M |
| September 01, 2026 | 140.84M |
| August 31, 2026 | 138.09M |
| August 28, 2026 | 140.51M |
| August 27, 2026 | 141.51M |
| August 26, 2026 | 148.13M |
| August 25, 2026 | 149.69M |
| August 24, 2026 | 147.54M |
| August 21, 2026 | 143.41M |
| August 20, 2026 | 147.69M |
| August 19, 2026 | 144.56M |
| August 18, 2026 | 145.64M |
| August 17, 2026 | 144.86M |
| August 14, 2026 | 150.81M |
| Date | Value |
|---|---|
| August 13, 2026 | 156.20M |
| August 12, 2026 | 156.05M |
| August 11, 2026 | 155.01M |
| August 10, 2026 | 156.39M |
| August 07, 2026 | 154.01M |
| August 06, 2026 | 158.06M |
| August 05, 2026 | 154.68M |
| August 04, 2026 | 147.84M |
| August 03, 2026 | 148.36M |
| July 31, 2026 | 155.12M |
| July 30, 2026 | 146.16M |
| July 29, 2026 | 144.27M |
| July 28, 2026 | 151.81M |
| July 27, 2026 | 151.15M |
| July 24, 2026 | 144.94M |
| July 23, 2026 | 154.16M |
| July 22, 2026 | 146.98M |
| July 21, 2026 | 148.43M |
| July 20, 2026 | 149.92M |
| July 17, 2026 | 148.91M |
| July 16, 2026 | 147.87M |
| July 15, 2026 | 149.69M |
| July 14, 2026 | 143.00M |
| July 13, 2026 | 146.16M |
| July 10, 2026 | 147.28M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Travere Therapeutics, Inc. | 6.038B |
| ACADIA Pharmaceuticals, Inc. | 3.815B |
| Alnylam Pharmaceuticals, Inc. | 31.72B |
| Anika Therapeutics, Inc. | 265.34M |
| Savara, Inc. | 960.37M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -23.42M |
| Revenue (Quarterly) | 15.60M |
| Total Expenses (Quarterly) | 39.02M |
| EPS Diluted (Quarterly) | -6.616 |
| Gross Profit Margin (Quarterly) | 68.40% |
| Profit Margin (Quarterly) | -150.1% |
| Earnings Yield | -115.4% |
| Normalized Earnings Yield | -88.41 |